1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Bioepis Sees Information Driving Utilization

Quarterly US Report Offers Detailed Information To Help Drive Biosimilar Uptake

 
• By Dave Wallace

By offering a detailed quarterly report on the US biosimilars market, Samsung Bioepis is hoping to help drive awareness and understanding, ultimately pushing up utilization, the firm’s US head of market access Tom Newcomer tells Generics Bulletin.

Tom Newcomer
Tom Newcomer is Samsung Bioepis’ US head of market access • Source: Samsung Bioepis

Earlier this year, Samsung Bioepis published the first in what is set to a be quarterly report on the US biosimilars market. Covering pricing data, uptake information and other topics relevant to the market – in the first report, interchangeability is in the spotlight – the report seeks to draw out market trends based on regularly-updated information across all biosimilar therapeutic categories.

Speaking to Generics Bulletin after the first report was published (see sidebar), Samsung Bioepis US head of market access Tom...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By Dean Rudge

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.

Medicines For Europe Sets Out Trade Priorities

 
• By Dave Wallace

As Medicines for Europe gears up for a pair of conferences in Brussels next week, the organization has set out trade policy recommendations to strengthen access to medicines and the competitiveness of EU manufacturing, in a seminar with representatives from the European Commission and member states.

More from Products

‘Disappointed’ Lipella Seeks Alternatives Following Nasdaq Delisting

 
• By Dean Rudge

Clinical-stage reformulation specialist Lipella Pharmaceuticals has insisted that “our commitment to our shareholders, our mission, and our clinical goals has not changed” after its common stock was delisted from the Nasdaq Capital Market.

Viatris Targets Gilead’s Odefsey HIV Blockbuster In Europe With CHMP Recommendation

 
• By Dean Rudge

Viatris has secured two positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use for generics to two blockbusters: Gilead’s HIV drug Odefsey and Boehringer’s IPF treatment Ofev, with a path to approvals possible in 67 days.

AAM Celebrates Court Backing Over Minnesota Pricing Law

 
• By Dave Wallace

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.